---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-009005"
form_type: "8-K"
ticker: "GLUE"
cik: "0001826457"
company_name: "Monte Rosa Therapeutics, Inc."
filed_at: "2026-01-09T23:59:59+00:00"
generated_at: "2026-05-16T11:05:24.035847+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Monte Rosa prices $300M public offering of common stock and pre-funded warrants

## Summary
- Offering of 11,125,000 shares at $24.00/share and pre-funded warrants for 1,375,000 shares at $23.9999 each.
- Gross proceeds ~$300M; estimated net ~$281.6M after discounts and expenses.
- Underwriters granted 30-day option to purchase up to 1,875,000 additional shares.
- Proceeds to fund MRT-8102 for atherosclerotic cardiovascular disease, QuEEN platform development, and working capital.
- Expects cash runway into 2029; closing expected on or about January 12, 2026.

## SEC filing metadata
- accession: 0001193125-26-009005
- form_type: 8-K
- ticker: GLUE
- cik: 0001826457
- company_name: Monte Rosa Therapeutics, Inc.
- filed_at: 2026-01-09T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 1.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1826457/000119312526009005/0001193125-26-009005-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1826457/000119312526009005/d36015d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-009005
- JSON: https://secwatch.observer/filing/0001193125-26-009005.json
- Plain text: https://secwatch.observer/filing/0001193125-26-009005.txt

## Key facts
- Material Agreements
  Monte Rosa Therapeutics, Inc. entered into Underwriting Agreement with Jefferies LLC, TD Securities (USA) LLC and Piper Sandler & Co., as representatives of the several underwriters valued at $24.00 per share (effective 2026-01-08).
  - Action: entry
  - Agreement: underwriting
  - Counterparty: Jefferies LLC, TD Securities (USA) LLC and Piper Sandler & Co., as representatives of the several underwriters
  - Value: $24.00 per share
  - Effective: 2026-01-08
  source text: On January 8, 2026, Monte Rosa Therapeutics, Inc. (the “Company”) entered into an Underwriting Agreement (the “Underwriting Agreement”) with Jefferies LLC, TD Securities (USA) LLC and Piper Sandler & Co., as representatives of the several underwriters listed on Schedule 1 thereto (collectively, the “Underwriters”), related to an underwritten public offering (the “Offering”) of 11,125,000 shares (the “Underwritten Shares”) of the Company’s common stock, par value $0.0001 per share (“Common Stock”), at a public offering price of $24.00 per share
  evidence_url: https://www.sec.gov/Archives/edgar/data/1826457/000119312526009005/0001193125-26-009005-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.